Raymond James upgraded Teleflex from Mkt Perform to Outperform and set a new price target of $128.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2026 | $128.00 | Mkt Perform → Outperform | Raymond James |
| 1/27/2026 | $138.00 | Hold → Buy | Needham |
| 3/4/2025 | $235.00 → $140.00 | Neutral → Underperform | BofA Securities |
| 2/28/2025 | $220.00 → $155.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/28/2025 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2025 | $255.00 → $140.00 | Overweight → Neutral | Piper Sandler |
| 2/27/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
Calls on Board to Establish Strategic Review Sub-Committee with New Independent Directors to Oversee Process Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today issued the following statement regarding the Company's recent announcement: "We welcome Teleflex's newfound openness to consider all strategic alternatives. As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder representative and excluding Dr. Klasko, to work with its advisors to both engage with inbound approaches and solicit outb
Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.
Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiv
Raymond James upgraded Teleflex from Mkt Perform to Outperform and set a new price target of $128.00
Needham upgraded Teleflex from Hold to Buy and set a new price target of $138.00
BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously
8-K - TELEFLEX INC (0000096943) (Filer)
SCHEDULE 13G/A - TELEFLEX INC (0000096943) (Subject)
8-K - TELEFLEX INC (0000096943) (Filer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiv
Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency me
Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period Adjusted diluted EPS from contin
Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.
Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi
Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that Stuart Randle, a member of the Company's Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Company. Dr. Stephen Klasko, the Company's Lead Director, has been named Chairman of the Board. The Board has engaged Spencer Stuart, a leading execu
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)